Lantheus (NASDAQ:LNTH) Given Hold (C-) Rating at Weiss Ratings

Key Points

• Lantheus (NASDAQ:LNTH) received a "hold (C-)" rating from Weiss Ratings, alongside mixed ratings from other analysts, with a consensus target price of $74.50.
• The company's stock opened at $53.55 and has a twelve-month low of $47.25 and a high of $118.21, reflecting significant volatility.
• Lantheus recently reported earnings of $1.57 per share, missing estimates and showing a 4.1% decline in revenue compared to the same quarter last year.

Lantheus (NASDAQ:LNTH - Get Free Report)'s stock had its "hold (c-)" rating reiterated by investment analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Other equities analysts have also recently issued research reports about the company. William Blair reiterated a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. JMP Securities decreased their price objective on Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a research note on Thursday, August 7th. The Goldman Sachs Group set a $77.00 price objective on Lantheus and gave the company a "neutral" rating in a research note on Wednesday. B. Riley decreased their price objective on Lantheus from $109.00 to $84.00 and set a "buy" rating for the company in a research note on Tuesday, September 16th. Finally, Truist Financial set a $63.00 price objective on Lantheus and gave the company a "hold" rating in a research note on Monday, August 11th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Lantheus has an average rating of "Moderate Buy" and a consensus target price of $74.50.

Lantheus Stock Performance

NASDAQ LNTH opened at $53.55 on Wednesday. The stock has a market cap of $3.64 billion, a PE ratio of 14.24 and a beta of 0.09. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49. Lantheus has a twelve month low of $47.25 and a twelve month high of $118.21. The stock has a fifty day simple moving average of $55.22 and a 200-day simple moving average of $75.38.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The business had revenue of $378.05 million for the quarter, compared to analysts' expectations of $389.69 million. During the same quarter in the prior year, the company posted $1.80 earnings per share. The business's revenue for the quarter was down 4.1% compared to the same quarter last year. Equities analysts anticipate that Lantheus will post 6.01 earnings per share for the current year.

Insider Activity at Lantheus

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of Lantheus stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares of the company's stock, valued at $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of Lantheus stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 6,812,000 shares of company stock worth $382,427,380. 1.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Elevation Point Wealth Partners LLC acquired a new position in Lantheus during the second quarter worth approximately $26,000. Signaturefd LLC grew its stake in shares of Lantheus by 36.5% in the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 116 shares during the last quarter. Osterweis Capital Management Inc. purchased a new position in shares of Lantheus in the 2nd quarter valued at approximately $36,000. Quarry LP grew its stake in shares of Lantheus by 2,350.0% in the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider's stock valued at $48,000 after purchasing an additional 470 shares during the last quarter. Finally, Hughes Financial Services LLC purchased a new position in shares of Lantheus in the 1st quarter valued at approximately $81,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.